Absci Corporation (ABSI)
| Market Cap | 754.39M |
| Revenue (ttm) | 2.80M |
| Net Income (ttm) | -115.18M |
| Shares Out | 153.02M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,827,575 |
| Open | 4.680 |
| Previous Close | 4.850 |
| Day's Range | 4.550 - 5.040 |
| 52-Week Range | 2.240 - 5.228 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | 6.96 (+41.18%) |
| Earnings Date | May 7, 2026 |
About ABSI
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Ket... [Read more]
Financial Performance
In 2025, Absci's revenue was $2.80 million, a decrease of -38.24% compared to the previous year's $4.53 million. Losses were -$115.18 million, 11.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price target is $6.96, which is an increase of 41.18% from the latest price.
News
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generat...
Absci Transcript: 25th Annual Needham Virtual Healthcare Conference
AI-driven platform targets the prolactin receptor for AGA and endometriosis, with ABS-201 advancing through clinical trials and key readouts expected this year. Market research shows strong demand for durable, low-frequency treatments, and commercialization will blend physician and direct-to-consumer strategies.
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generat...
Absci Earnings Call Transcript: Q4 2025
ABS-201 advanced in clinical trials for AGA and endometriosis, showing favorable safety and strong market interest. Q4 2025 saw increased R&D spending and a solid cash position, supporting operations into 2028 and ongoing strategic partnerships.
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data
Absci Transcript: Leerink Global Healthcare Conference 2026
The platform leverages AI to develop assets for hard-to-target indications, with ABS-201 advancing in both AGA and endometriosis. Key clinical milestones are expected over the next 24 months, supported by strong financials and a focus on differentiated product profiles.
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generat...
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue t...
Absci Transcript: TD Cowen 46th Annual Health Care Conference
Agentic AI is rapidly transforming drug discovery, with asset creation—especially ABS-201 for hair regrowth—seen as the main value driver. ABS-201 targets a $25B+ market, with efficient development and broad patient appeal, while the pipeline strategy balances internal development and early out-licensing.
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026
VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generati...
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, to...
Absci Transcript: 44th Annual J.P. Morgan Healthcare Conference
Origin-1, a new AI model, enables rapid, cost-effective design of first-in-class antibodies for hard-to-drug targets. ABS-201 is advancing in trials for androgenic alopecia and endometriosis, with major readouts expected in the next 24 months. Market research shows strong demand and a multibillion-dollar opportunity.
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, to...
Absci Transcript: Status Update
ABS-201, an AI-designed prolactin receptor antibody, targets a major unmet need in hair loss with robust preclinical efficacy, a favorable safety profile, and strong patient interest. The ongoing phase 1/2a trial aims for durable, convenient treatment, with a $25B+ U.S. market opportunity.
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research
Partnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational...
Absci Transcript: Jefferies London Healthcare Conference 2025
A generative AI-driven drug discovery platform is advancing ABS-201 for androgenic alopecia and endometriosis, with phase 2 readouts expected in 24 months. Strong preclinical data, a robust financial position, and major partnerships support a differentiated pipeline.
Absci Earnings Call Transcript: Q3 2025
ABS-201 clinical development accelerated for both AGA and endometriosis, with key trials starting in late 2025 and 2026. ABS-101 will be partnered out after phase I, and strong cash reserves support operations into 2028. Multi-billion dollar market opportunities and new partnerships are anticipated.
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
Reported interim results for Phase 1 trial for ABS-101 (anti-TL1A) On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December 11 E...
Absci Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The conference highlighted significant progress in generative AI-driven antibody design, with ABS-201 advancing toward clinical trials for hair regrowth and endometriosis. The company is well-funded, expects key data readouts next year, and is preparing for both physician-led and direct-to-consumer commercialization.
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the comp...
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance VANCOUVER, Wash....
Absci Boosts AI-Powered Drug Discovery With Oracle And AMD Collaboration
Absci Inc. ABSI on Thursday collaborated with Oracle Corporation's ORCL Oracle Cloud Infrastructure (OCI) and AMD Inc. AMD to accelerate generative AI-driven drug discovery.
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs Performance and scalability of Oracle Cloud Infrastruc...